http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020083933-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8978bd38ca49e2bac8e485bf25381ed1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-915 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-91 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| filingDate | 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80c16ae9ae28e7d99a33b53d0ab49ed3 |
| publicationDate | 2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020083933-A1 |
| titleOfInvention | Fusion polypeptides and therapeutic applications thereof |
| abstract | Isolated fusion polypeptide comprising a first amino acid sequence characterized by at least (≥)85% sequence identity to SEQ ID NO 01 -SEQ NO 04, SEQ ID 23 or SEQ ID 08 said first amino acid sequence and/or said isolated fusion protein having an NAD+-dependent deacetylase function identical to SIRT1 isoform 1, isoform 2, isoform b or isoform c or the catalytic domain thereof, said first amino acid sequence being directly or indirectly chemically linked to at least one of second amino acid sequence comprising a fragment crystallizable (Fc) region or an albumin, or a post- translationally modified derivative thereof, for use in a method of treatment amelioration, mitigation, slowing, arresting, reversing or prevention of an age-related diseases or of a condition selected from the group consisting of: mitochondrial-related diseases/disorders, metabolic disorders, neurodegenerative diseases, polyglutamine diseases, anticoagulation and antithrombotic conditions, allergies and respiratory conditions, autoimmune diseases, vision impairment, but also dyslipidemia, hyperlipidemia, diabetes, metabolic syndrome, inflammation, apoptosis, neurodegeneration, cancer, hypercholesterolemia, atherosclerosis, cardiovascular disease (CVD), steatohepatitis (fatty liver disease), pancreatitis, renal lipid deposition, and obesity-related conditions. |
| priorityDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 982.